JP5373788B2 - Ｆｘｒを調節するための化合物および方法 - Google Patents

Ｆｘｒを調節するための化合物および方法 Download PDF

Info

Publication number
JP5373788B2
JP5373788B2 JP2010517082A JP2010517082A JP5373788B2 JP 5373788 B2 JP5373788 B2 JP 5373788B2 JP 2010517082 A JP2010517082 A JP 2010517082A JP 2010517082 A JP2010517082 A JP 2010517082A JP 5373788 B2 JP5373788 B2 JP 5373788B2
Authority
JP
Japan
Prior art keywords
phenyl
cyclopropyl
dichloro
isoxazol
ylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010517082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010533722A (ja
JP2010533722A5 (https=
Inventor
マイケル・ジェイムズ・ジェニン
フランシスコ・ハビエル・アヘハス−チチャロ
アナ・ベレン・ブエノ・メレンド
ピーター・ルドルフ・マニネン
アラン・エム・ウォシャウスキー
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2010533722A publication Critical patent/JP2010533722A/ja
Publication of JP2010533722A5 publication Critical patent/JP2010533722A5/ja
Application granted granted Critical
Publication of JP5373788B2 publication Critical patent/JP5373788B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
JP2010517082A 2007-07-16 2008-07-11 Ｆｘｒを調節するための化合物および方法 Active JP5373788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94997407P 2007-07-16 2007-07-16
US60/949,974 2007-07-16
PCT/US2008/069719 WO2009012125A1 (en) 2007-07-16 2008-07-11 Compounds and methods for modulating fxr

Publications (3)

Publication Number Publication Date
JP2010533722A JP2010533722A (ja) 2010-10-28
JP2010533722A5 JP2010533722A5 (https=) 2011-08-11
JP5373788B2 true JP5373788B2 (ja) 2013-12-18

Family

ID=39855171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517082A Active JP5373788B2 (ja) 2007-07-16 2008-07-11 Ｆｘｒを調節するための化合物および方法

Country Status (31)

Country Link
US (1) US8153624B2 (https=)
EP (1) EP2178851B1 (https=)
JP (1) JP5373788B2 (https=)
KR (1) KR101157334B1 (https=)
CN (1) CN101743232B (https=)
AR (1) AR067540A1 (https=)
AT (1) ATE539065T1 (https=)
AU (1) AU2008276236B2 (https=)
BR (1) BRPI0814571A2 (https=)
CA (1) CA2693406C (https=)
CL (1) CL2008002051A1 (https=)
CO (1) CO6270212A2 (https=)
CY (1) CY1112298T1 (https=)
DK (1) DK2178851T3 (https=)
DO (1) DOP2010000018A (https=)
EA (1) EA016475B1 (https=)
EC (1) ECSP109879A (https=)
ES (1) ES2376176T3 (https=)
HR (1) HRP20120048T1 (https=)
IL (1) IL202234A0 (https=)
MA (1) MA31683B1 (https=)
MX (1) MX2010000502A (https=)
PE (1) PE20090809A1 (https=)
PL (1) PL2178851T3 (https=)
PT (1) PT2178851E (https=)
RS (1) RS52216B (https=)
SI (1) SI2178851T1 (https=)
SV (1) SV2010003458A (https=)
TN (1) TN2010000028A1 (https=)
TW (1) TW200906823A (https=)
WO (1) WO2009012125A1 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655368A1 (en) * 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
WO2012087521A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
DK3043865T3 (da) 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
BR112016009630B1 (pt) 2013-11-05 2021-02-09 Novartis Ag receptores de farnesoide x, seus usos, combinação e composição farmacêutica
CN104045635A (zh) * 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TW201628625A (zh) 2015-02-06 2016-08-16 英特賽普醫藥品公司 組合療法醫藥組成物
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
CN107021958A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
JPWO2017170434A1 (ja) 2016-03-28 2019-01-31 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
WO2017189651A1 (en) * 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN116854681A (zh) 2016-08-23 2023-10-10 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
RU2019110779A (ru) * 2016-09-14 2020-10-15 Новартис Аг Новые схемы введения агонистов fxr
US10450306B2 (en) * 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
PL3612520T3 (pl) * 2017-04-12 2022-03-21 Il Dong Pharmaceutical Co., Ltd. Pochodne izoksazolu jako agoniści receptora jądrowego i ich zastosowania
CN109265471B (zh) * 2017-06-30 2021-06-04 轩竹生物科技有限公司 Fxr受体激动剂
CN109320509B (zh) * 2017-07-31 2022-02-08 轩竹生物科技股份有限公司 Fxr受体激动剂
EP3681881B1 (en) 2017-09-14 2022-11-02 Ardelyx, Inc. Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
CN111511731B (zh) * 2017-11-01 2023-05-23 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃化合物
AU2018360575A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
KR102731924B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
KR20200102415A (ko) * 2017-12-22 2020-08-31 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 이소옥사졸 유도체, 그 제조 방법 및 그 용도
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN110452235B (zh) * 2018-05-08 2023-02-17 中国科学院上海药物研究所 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途
SG11202101863YA (en) * 2018-08-30 2021-03-30 Terns Pharmaceuticals Inc Treating liver disorders
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
AU2020221371A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
CN113727973B (zh) 2019-02-15 2025-08-29 百时美施贵宝公司 可用作类法尼醇x受体调节剂的取代酰胺化合物
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
KR20250076664A (ko) 2019-04-19 2025-05-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Fxr 소분자 작용제 및 이의 제조 방법과 용도
WO2020231917A1 (en) * 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN114144185A (zh) 2019-05-30 2022-03-04 英特塞普特医药品公司 用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
CN114667142A (zh) * 2019-11-08 2022-06-24 拓臻制药公司 治疗肝脏病症
WO2021108974A1 (en) 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
IL298144A (en) * 2020-05-13 2023-01-01 Terns Pharmaceuticals Inc Combination treatment of liver disorders
JP2023539639A (ja) 2020-08-25 2023-09-15 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤の多形
US20220098184A1 (en) * 2020-09-11 2022-03-31 Terms Pharmaceuticals, Inc. Solid dispersion formulations of an fxr agonist
IL302099A (en) * 2020-10-15 2023-06-01 Lilly Co Eli Polymorphs of an fxr agonist
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
TW202327589A (zh) 2021-11-11 2023-07-16 美商拓臻製藥公司 肝病之組合療法
WO2023220404A1 (en) * 2022-05-13 2023-11-16 Terns Pharmaceuticals, Inc. Treatment of non-alcoholic steatohepatitis
CN115850152B (zh) * 2022-12-20 2025-10-31 河北鼎泰制药有限公司 一种杂质A-7-imp3的制备方法及其用途
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7105556B2 (en) * 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
BR0312503A (pt) 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
CA2640476A1 (en) * 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
TW200812982A (en) 2006-05-24 2008-03-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101448791B (zh) 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂

Also Published As

Publication number Publication date
CO6270212A2 (es) 2011-04-20
WO2009012125A1 (en) 2009-01-22
AU2008276236A1 (en) 2009-01-22
KR20100020999A (ko) 2010-02-23
TN2010000028A1 (en) 2011-09-26
HRP20120048T1 (hr) 2012-02-29
DK2178851T3 (da) 2012-02-06
KR101157334B1 (ko) 2012-06-15
SV2010003458A (es) 2011-01-10
ES2376176T3 (es) 2012-03-09
EA201070148A1 (ru) 2010-06-30
IL202234A0 (en) 2010-06-16
DOP2010000018A (es) 2010-01-31
EA016475B1 (ru) 2012-05-30
AR067540A1 (es) 2009-10-14
PE20090809A1 (es) 2009-06-27
JP2010533722A (ja) 2010-10-28
RS52216B (sr) 2012-10-31
CN101743232A (zh) 2010-06-16
EP2178851A1 (en) 2010-04-28
CN101743232B (zh) 2013-03-06
US20100152166A1 (en) 2010-06-17
CY1112298T1 (el) 2015-12-09
PT2178851E (pt) 2012-02-27
ECSP109879A (es) 2010-02-26
EP2178851B1 (en) 2011-12-28
CA2693406C (en) 2014-04-29
BRPI0814571A2 (pt) 2015-01-06
US8153624B2 (en) 2012-04-10
ATE539065T1 (de) 2012-01-15
MX2010000502A (es) 2010-03-26
PL2178851T3 (pl) 2012-05-31
CL2008002051A1 (es) 2009-05-29
TW200906823A (en) 2009-02-16
SI2178851T1 (sl) 2012-02-29
MA31683B1 (fr) 2010-09-01
CA2693406A1 (en) 2009-01-22
AU2008276236B2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
JP5373788B2 (ja) Ｆｘｒを調節するための化合物および方法
DK2467366T3 (en) New FXR (NR1H4) Binding and Activity Modulating Compounds
EA015632B1 (ru) Агонисты fxr
CA2651373A1 (en) Compounds and methods for modulating fxr
MX2011002794A (es) Indazol 2,3-sustituido o 4,5,6,7-tetrahidro-indazol como moduladores fxr contra dislipidemia y enfermedades relacionadas.
WO2009149795A2 (en) Heterocyclic cyclopropyl-substituted fxr binding compounds
JP2010280680A (ja) インドール−３−硫黄誘導体
KR20050010507A (ko) 신규 치환 인돌
US11052092B2 (en) N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
TW201012815A (en) Aryl isoxazole compounds with antitumoural activities
WO2009128558A1 (ja) ペルオキシソーム増殖剤活性化受容体の活性化剤
WO2015024448A1 (zh) 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
CN101287722A (zh) 作为代谢型谷氨酸受体拮抗剂的取代的哌嗪
CA2815741A1 (en) Triazole derivatives as ligands for gaba receptors
JPH11509532A (ja) 片頭痛治療用の１，６−二置換イソクロマン
JP2023545677A (ja) Ｆｘｒ小分子アゴニストとその調製方法および用途
US9796726B2 (en) Dihydroquinoline pyrazolyl compounds
HK1251552B (zh) 含羟基的fxr(nr1h4)调节化合物
HU211690A9 (hu) Az átmeneti oltalom az 1—18. igénypontokra vonatkozik.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130919

R150 Certificate of patent or registration of utility model

Ref document number: 5373788

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250